243 related articles for article (PubMed ID: 29242082)
1. Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
Polis CB; Achilles SL; Hel Z; Hapgood JP
Contraception; 2018 Mar; 97(3):191-197. PubMed ID: 29242082
[No Abstract] [Full Text] [Related]
2. Progestin-only contraception: injectables and implants.
Jacobstein R; Polis CB
Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):795-806. PubMed ID: 24996766
[TBL] [Abstract][Full Text] [Related]
3. New aspects of injectable contraception.
Phillips OP
Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
[TBL] [Abstract][Full Text] [Related]
4. HIV, progestins, genital epithelial barrier function, and the burden of objectivity†.
Vicetti Miguel RD; Quispe Calla NE; Cherpes TL
Biol Reprod; 2020 Aug; 103(2):318-322. PubMed ID: 32561906
[TBL] [Abstract][Full Text] [Related]
5. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
6. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
7. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo.
Abasiattai AM; Udoma EJ; Ukeme E
Ann Afr Med; 2010; 9(2):81-5. PubMed ID: 20587929
[TBL] [Abstract][Full Text] [Related]
8. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
[TBL] [Abstract][Full Text] [Related]
9. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
10. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
11. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.
Zia Y; Tang JH; Chinula L; Tegha G; Stanczyk FZ; Kourtis AP
Contraception; 2019 Nov; 100(5):402-405. PubMed ID: 31374188
[TBL] [Abstract][Full Text] [Related]
13. Current concepts regarding use of DMPA.
Kaunitz AM
J Reprod Med; 2002 Sep; 47(9 Suppl):785-9. PubMed ID: 12380407
[TBL] [Abstract][Full Text] [Related]
14. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
15. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
Renner RM; Edelman AB; Kaunitz AM
Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
[No Abstract] [Full Text] [Related]
16. Injectable contraception.
Mishell DR
J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
[No Abstract] [Full Text] [Related]
17. Current options for injectable contraception in the United States.
Kaunitz AM
Semin Reprod Med; 2001 Dec; 19(4):331-7. PubMed ID: 11727175
[TBL] [Abstract][Full Text] [Related]
18. Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).
Stout A; Wood S; Namagembe A; Kaboré A; Siddo D; Ndione I
Eval Program Plann; 2018 Jun; 68():185-193. PubMed ID: 29609057
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate.
Hapgood JP
Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710
[No Abstract] [Full Text] [Related]
20. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
Jain AK
Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
